| | Diabetes | | | Taking Control of Glycemia in Type 2 Diabetes Patients with Cardiovascular Risk
Overview
More than 20 million people in the United States are affected by diabetes, with 1.5 million new cases appearing each year. Of this population, nearly 65% will die from heart disease or stroke, a rate that is 4-times higher than in the non-diabetic population. Individualized and early glycemic control is critical in the prevention and management of diabetes and in reducing cardiovascular risk. This activity will expose attendees to the relationship between insulin resistance, type 2 diabetes, and the resulting cardiovascular risk in an effort to uncover effective treatment strategies and patient-based therapeutic options.
Objectives
Utilize appropriate glucose-lowering agents to reduce A1C to ? 7.0%
Minimize adverse events and cardiovascular risk associated with glycemic therapy by employing appropriate glucose, blood pressure, and serum cholesterol agents
Faculty
Mark Stolar, MD
Associate Professor of Clinical Medicine
Northwestern University
The Feinberg School of Medicine
Chicago, IL
Patrick J. Boyle, MD
Professor of Medicine
University of New Mexico
Albuquerque, NM
| | | PAD | | | Prevent the Event: Early Detection and Management of the PAD Patient
Overview
PAD is frequently unrecognized and many patients at risk are currently not identified and treated. Current estimates are that 8-12 million Americans have PAD, with the highest incidence among those over 70 years of age, regardless of health status, and people over 50 years of age with diabetes mellitus.
Today's This lecture will overview the tremendous risk associated with PAD, discuss the major risk factors for developing PAD, and highlight the role of primary care in detecting and diagnosing the condition through increased use of ABI screening. Current therapies will be discussed including symptom improvement and prevention of future CV events with an emphasis on patient compliance issues.
Objectives
Name the two types of patients most at risk of PAD who should be screened utilizing ABI
Recognize the need and benefits of ABI, and describe what readings are considered abnormal
Faculty
Richard V. Milani, MD
| | | IBS | | | Success in IBS: Deconstructing the Barriers to Optimal Management in Irritable Bowel Syndrome
Overview
Irritable bowel syndrome (IBS) is a highly misunderstood functional bowel disorder that is underreported and underdiagnosed. Because IBS can be challenging to diagnose and manage, it is important that clinicians stay up-to-date on current developments of diagnostic and treatment options in IBS.
Objectives
Recognize the symptoms of IBS and employ ACG guidelines and Rome III criteria to make a symptom-based diagnosis of IBS
Implement a patient-centered and evidence-based approach to the treatment of IBS, taking patients' treatment goals into consideration as well as the efficacy, safety, and mechanisms of action of available treatment options
Faculty
Louis Kuritzky, MD
Clinical Assistant Professor
Department of Community Health & Family Medicine
University of Florida
Gainesville, FL
David A. Peura, MD
Professor of Medicine
University of Virginia Health Sciences Center
Charlottesville, VA
| | | Hypertension | | | Management of the Moderate-to-Severe Hypertensive: Individualizing Treatment to Maximize Outcomes
Overview
This program will underscore the need for early, aggressive, combination BP treatment in order to reach JNC 7 goals, in light of the effect hypertension and diabetes has on the pathogenesis of hypertensive renal damage. It will explain the mechanisms of action of the various antihypertensive drug classes and how clinicians can use this understanding when selecting a drug regimen. Based on recent and ongoing trials, the safest and most efficacious drug combinations will be discussed.
Objectives
Develop appropriate combination therapy regimens individualized to each diabetic hypertensive patient's established risk and comorbid conditions
Demonstrate an understanding of the role of renin-aniotensin-aldosterone system blockers in the treatment of hypertension, the prevention of new onset diabetes, and the prevention of progression in diabetic nephropathy by selecting the most appropriate treatment regimen for diabetic hypertensive patients
Faculty
Philip Altus, MD, MACP
Professor Emeritus, Department of Medicine
University of South Florida
Tampa, FL
Domenic A. Sica, MD
Professor of Medicine
Medical College of Virginia
Virginia Commonwealth University
Richmond, VA
| | | Rhinitis | | | Allergic Rhinitis and Its Comorbidities: A Serious Challenge to the Healthcare Professional
Overview
Allergic rhinitis (AR) is the most common allergic condition in the US, affecting nearly 40 million people. Although AR is associated with significant comorbidities, current therapies have proven only modestly successful. Allergic Rhinitis and Its Comorbidities: A Serious Challenge to the Health Care Professional will provide primary care physicians with practical, evidence-based solutions to the challenges of managing AR, with particular emphasis on finding effective treatments and ensuring patient compliance. Two nationally recognized allergy/immunology experts will lead each 75-minute presentation with 60 minutes of didactic lectures and case history presentation, and a 15-minute question-and-answer session. Interactive discussion and a dynamic audience response system will also be integrated into the session.
Objectives
Describe key clinical characteristics of allergic rhinitis, its associated comorbidities, and its impact on patient health and quality of life
Identify barriers to treatment success of allergic rhinitis (treatment-related, physician-related, and patient-related barriers) and adequate control of symptoms, and devise strategies for overcoming those barriers
Faculty
Dennis K. Ledford, MD
| | | Zoster Virus | | | Preventing Herpes Zoster and Postherpetic Neuralgia: Are Your Patients Adequately Protected?
Overview
An estimated 1 million cases of herpes zoster (shingles) occur annually in the United States. The incidence and severity of herpes zoster increase with advancing age to produce substantial negative effects on quality of life, activities of daily living, neuropsychological functioning, and social status, resulting in significant morbidity in older adults. While antiviral therapy reduces the incidence and severity of herpes zoster, it does not reliably prevent postherpetic neuralgia (PHN), the most common and debilitating clinical sequela of herpes zoster. Herpes zoster vaccination has been demonstrated to reduce the incidence of the disease and its complications. Clinical trial data have demonstrated significant reductions in the incidence of herpes zoster and PHN, as well as overall reductions in the burden of disease.
Objectives
Review the benefits and limitations of current treatment options for herpes zoster and postherpetic neuralgia (PHN)
Evaluate clinical trial results of the herpes zoster vaccine and discuss current recommendations of the Advisory Committee on Immunization Practices for the prevention of herpes zoster
Faculty
Malcolm Fraser, MD, CMD
President, Bay Geriatrics
St. Petersburg, FL
John F. Trowbridge, MD, CPE
Director, Chronic Conditions Management
Kaiser Permanente Santa Rosa
Clinical Professor of Medicine
University of California at San Francisco
San Francisco, CA
| | | Mood Disorders | | | Managing Mood and Anxiety Disorders in Primary Care Practice: A Focus on Complex and Difficult-to-Treat Patients
Overview
Bipolar disorder (BD) and major depressive disorder (MDD) are two of the most prevalent psychiatric disorders in adults. These conditions are associated with overlapping disorders of mood including anxiety and depression; differentiating the two disorders can be difficult and can lead to misdiagnosis and mismanagement. This activity will focus on practical approaches to the diagnosis and management of the "difficult-to-treat" patient presenting with depression associated with MDD and BD.
Objectives
Recognize overlapping symptomatology and comorbid psychiatric disorders that can complicate the differential diagnosis of depression
Design and implement practical strategies to diagnosis and manage the difficult-to-treat patient with depression associated with major depressive disorder and bipolar disorder
Faculty
Larry Culpepper, MD, MPH
Professor of Family Medicine
Department of Family Medicine Chair
Boston University School of Medicine
Boston, MA
Chief of Family Practice
Boston Medical Center
Boston, MA
Robert M.A. Hirschfeld, MD
Titus H. Harris Chair
Harry K. Davis Professor
Professor and Chairperson
Department of Psychiatry and Behavioral Sciences
University of Texas Medical Branch
Galveston, TX
| | | Acne / Actinic Keratosis | | | More Than Skin Deep: Clinical Strategies for Acne Vulgaris and Actinic Keratosis
Overview
"More Than Skin Deep: Clinical Strategies for Acne Vulgaris and Actinic Keratosis" is a continuing medical education program that aims to bridge some of the existing professional practice gaps that primary care clinicians may have regarding common dermatologic problems. This program will educate clinicians in the primary care setting about the prevalence, impact, diagnosis, and treatment of both acne vulgaris and actinic keratosis.
Objectives
Confidently diagnose patients presenting with the basic dermatologic conditions of acne vulgaris and actinic keratosis.
If you are uncertain if a patient has actinic keratosis, don't hesitate to refer patient for dermatologic consultation.
Faculty
Joseph L. Jorizzo, MD
Professor, Founder and Former Chair Department of Dermatology
Winston-Salem, NC
Guy Webster, PhD
| | | HPV | | | Reducing the Burden of HPV-Related Diseases: Cervical Cancer and Beyond
Overview
Human papillomavirus (HPV) is the most common newly acquired sexually transmitted infection in the United States. It is a necessary cause of cervical cancer and genital warts, and is associated with other anogenital and head and neck cancers, and recurrent respiratory papillomatosis. Prevention of HPV infection through prophylactic vaccination provides a safe and effective option to reduce the health burden associated with HPV-related diseases. Two vaccines have been developed: a quadrivalent HPV (6, 11, 16, 18) vaccine, approved by the US Food and Drug Administration (FDA), and a bivalent HPV (16, 18) vaccine, currently under FDA review. Both vaccines have demonstrated lasting efficacy against HPV-associated cervical disease and are generally well tolerated. This program will review the health consequences of HPV infection; provide an update on the safety and efficacy of HPV vaccines, including recent data on efficacy in mid-adult women, duration of protection, and cross-protection against nonvaccine HPV types; and evaluate the benefits of widespread HPV vaccination in preventing HPV-related diseases.
Objectives
Describe the epidemiology, natural history and consequences of HPV infection
Evaluate the anticipated benefits of widespread HPV vaccination in preventing cervical and anogenital cancers, genital warts, and other HPV-related diseases
Faculty
Richard E. Rupp, MD
Associate Director, Division of Adolescent and Behavioral Medicine
Associate Professor of Pediatrics
University of Texas Medical Branch at Galveston
Galveston, TX
Lawrence S. Friedman, MD
Professor of Pediatrics and Internal Medicine
University of California, San Diego
Medical Director, Ambulatory Care and Quality and Safety
UCSD Medical Center
San Diego, CA
| | | | | |
Overview
Objectives
Faculty
|
|
